ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

China flag China · Delayed Price · Currency is CNY
38.80
+0.50 (1.31%)
Mar 10, 2026, 3:00 PM CST
137.21%
Market Cap 6.11B
Revenue (ttm) 741.34M
Net Income (ttm) 165.82M
Shares Out 157.39M
EPS (ttm) 1.05
PE Ratio 36.95
Forward PE 22.56
Dividend 0.06 (0.17%)
Ex-Dividend Date Nov 17, 2025
Volume 2,468,467
Average Volume 2,181,455
Open 38.47
Previous Close 38.30
Day's Range 37.84 - 39.07
52-Week Range 15.88 - 47.97
Beta 0.75
RSI 50.48
Earnings Date Apr 24, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. Che... [Read more]

Sector Healthcare
Founded 2001
Employees 1,450
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688117
Full Company Profile

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.34 million, an increase of 62.55% compared to the previous year's 456.07 million. Earnings were 165.82 million, an increase of 231.49%.

Financial Statements

News

There is no news available yet.